Axsome Therapeutics Inc (AXSM)

[BioSpecialist]

2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM

AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL

Axsome Therapeutics (AXSM)

Market Cap: $120 M
Cash $40 M
Price: $4.75

Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)


Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf


Anticipated Near-Term Clinical Milestones

• Clinical Trial Readouts:

Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)

Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)

Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)


Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017
https://www.themarketsdaily.com/2017/12/04/axsome-therapeutics-inc-axsm-stake-owned-by-sabby-management-llc.html